INS and metabolic dysfunction-associated steatotic liver disease: The key objectives of the present study are to investigate the effect of insulin sensitizers (rosiglitazone and metformin), ezetimibe, and valsartan (each alone or in combinations) on plasma PON activity and PON-mRNA expression in the liver and the potential protective role in NAFLD.